Pfizer Inc. $PFE Shares Sold by Castle Wealth Management LLC

Castle Wealth Management LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,679 shares of the biopharmaceutical company’s stock after selling 889 shares during the quarter. Castle Wealth Management LLC’s holdings in Pfizer were worth $210,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PFE. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. acquired a new stake in Pfizer during the 2nd quarter worth approximately $29,000. Finally, Horizon Financial Services LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PFE shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Bank of America increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Stock Performance

Pfizer stock opened at $24.72 on Thursday. The stock has a market cap of $140.52 billion, a P/E ratio of 13.15, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a 50 day moving average of $24.88 and a 200-day moving average of $24.13. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.17.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.